AVX754 (nucleoside reverse transcriptase inhibitor) to treat drug resistant HIV

Phase 2

Recruiting

• Conditions: HIV Infections; Infection - Acquired immune deficiency syndrome (AIDS / HIV)

• Registration Number: ACTRN12605000742673
• Lead Sponsor: Avexa Ltd

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2005-11-15
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

Informed consentHIV-1 infectedM184V mutation in reverse transcriptaseCurrently taking lamivudineViral load >2,000 copies/mlCD4+ T-cell count>50 cells.

Exclusion Criteria

Hep B surface Antigen PositivePregnant or breast feeding femalesHepatitis C RNA positive requiring treatment.

Study & Design

• Study Type: Interventional
• Study Design: Not specified